Logo image of NVAX

NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD

8.17  +0.25 (+3.16%)

Fundamental Rating

2

NVAX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of NVAX have multiple concerns. NVAX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
In the past 5 years NVAX reported 4 times negative operating cash flow.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500M -1B -1.5B

1.2 Ratios

The Return On Assets of NVAX (-16.63%) is better than 80.99% of its industry peers.
Industry RankSector Rank
ROA -16.63%
ROE N/A
ROIC N/A
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K 5K

1.3 Margins

The Gross Margin of NVAX (63.79%) is better than 80.82% of its industry peers.
NVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

1

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NVAX has been increased compared to 1 year ago.
Compared to 5 years ago, NVAX has more shares outstanding
Compared to 1 year ago, NVAX has an improved debt to assets ratio.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NVAX has an Altman-Z score of -3.78. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX's Altman-Z score of -3.78 is in line compared to the rest of the industry. NVAX outperforms 42.81% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.78
ROIC/WACCN/A
WACC9.07%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

NVAX has a Current Ratio of 0.93. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of NVAX (0.93) is worse than 88.99% of its industry peers.
NVAX has a Quick Ratio of 0.93. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.93, NVAX is doing worse than 87.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.52% over the past year.
Looking at the last year, NVAX shows a very negative growth in Revenue. The Revenue has decreased by -15.68% in the last year.
The Revenue has been growing by 95.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.68%
Revenue 1Y (TTM)-15.68%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Sales Q2Q%-54.8%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.98% on average per year.
NVAX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.75% yearly.
EPS Next Y73.29%
EPS Next 2Y42.69%
EPS Next 3Y29.51%
EPS Next 5Y17.98%
Revenue Next Year-28.64%
Revenue Next 2Y-25.89%
Revenue Next 3Y-13.71%
Revenue Next 5Y-12.75%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVAX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 41.08 indicates a quite expensive valuation of NVAX.
Based on the Price/Forward Earnings ratio, NVAX is valued cheaply inside the industry as 92.18% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.06, NVAX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 41.08
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NVAX's earnings are expected to grow with 29.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.69%
EPS Next 3Y29.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVAVAX INC

NASDAQ:NVAX (2/21/2025, 1:39:08 PM)

8.17

+0.25 (+3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners54.64%
Inst Owner Change9.89%
Ins Owners0.3%
Ins Owner Change8.77%
Market Cap1.31B
Analysts76.67
Price Target17.75 (117.26%)
Short Float %22.82%
Short Ratio8.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.4%
Min EPS beat(2)-40.73%
Max EPS beat(2)5.92%
EPS beat(4)2
Avg EPS beat(4)-61.61%
Min EPS beat(4)-214.89%
Max EPS beat(4)5.92%
EPS beat(8)5
Avg EPS beat(8)-26.55%
EPS beat(12)5
Avg EPS beat(12)-98.18%
EPS beat(16)6
Avg EPS beat(16)-79.7%
Revenue beat(2)1
Avg Revenue beat(2)0.58%
Min Revenue beat(2)-11.17%
Max Revenue beat(2)12.33%
Revenue beat(4)1
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-11.29%
Max Revenue beat(4)12.33%
Revenue beat(8)3
Avg Revenue beat(8)6.56%
Revenue beat(12)4
Avg Revenue beat(12)-4.95%
Revenue beat(16)5
Avg Revenue beat(16)-3.4%
PT rev (1m)0%
PT rev (3m)-11.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-182.78%
EPS NY rev (1m)-1.52%
EPS NY rev (3m)-79.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-76.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.08
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)0.2
Fwd EY2.43%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS5.53
BVpS-3.29
TBVpS-4.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.79%
FCFM N/A
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.72%
Cap/Sales 2.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z -3.78
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)300.93%
Cap/Depr(5y)410.08%
Cap/Sales(3y)5.06%
Cap/Sales(5y)7.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.68%
EPS Next Y73.29%
EPS Next 2Y42.69%
EPS Next 3Y29.51%
EPS Next 5Y17.98%
Revenue 1Y (TTM)-15.68%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Sales Q2Q%-54.8%
Revenue Next Year-28.64%
Revenue Next 2Y-25.89%
Revenue Next 3Y-13.71%
Revenue Next 5Y-12.75%
EBIT growth 1Y52.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.76%
EBIT Next 3Y27.97%
EBIT Next 5YN/A
FCF growth 1Y84.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.82%
OCF growth 3YN/A
OCF growth 5YN/A